Sunday, 19 August 2018

Internal Sessions
11:00 - 12:30
Auditorium Lumière

IAPRD Annual General Meeting (for full IAPRD members only)

Plenary Session
13:30 - 15:00
Auditorium Lumière

The Structure and Function of the Basal Ganglia
Chair: M. Angela Cenci (Lund, Sweden)
Chair: Thomas Bruecke (Vienna, Austria)

Untangling the Neurophysiology of the Basal Ganglia 13:30 - 14:00
Speaker: Hagai Bergman (Jerusalem, Israel)

Deconstructing the Neurochemistry of the Basal Ganglia 14:00 - 14:30
Speaker: M. Angela Cenci (Lund, Sweden)

Basal Ganglia Circuits: A Review with Lessons from Neuromodulation 14:30 - 15:00
Speaker: Michael Okun (Gainesville, United States)

Poster
15:00 - 20:00
Exhibition Forum 3

Topic: Deep Brain Stimulation and Functional Neurosurgery

Improvement of apraxia of eyelid opening in a patient with Parkinson’s disease following the change of the directional lead for subthalamic nucleus deep brain stimulation.

Toe dystonia in Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation
Speaker: Chloe Laurencin (Lyon, France)

Long term outcome of the subthalamic nucleus DBS for advanced Parkinson’s disease: An eight years follow-up study in China

The long-term development of excessive daytime sleepiness after subthalamic deep brain stimulation in patients with Parkinson’s disease

Usefulness of directional deep brain stimulation in patients with movement disorders

Predicting patient discharge disposition subsequent to deep brain stimulation surgery: A pilot study

Meta-analysis of mortality following subthalamic and pallidal deep brain stimulation for patients with Parkinson’s disease
**Topic: Other Parkinsonian Disorders**

- When PSP and CBD overlap: A case report
- Effects of green tea extract on Parkinsonism and related disorders; neuroleptic anxiety syndrome, growth & pain
- Features of the course of Parkinson’s disease in congenital anomalies of cerebral vessels
- Pharmacologic approaches in dementia with Lewy bodies: Lessons learned from a case series
- Levosulpiride induced persistent movement disorders: case series
- Single photon emission computer tomography in the differentiation of progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy
- Movement disorders in bilateral striatopallidodentate calcinosis (Fahr’s syndrome): an analysis of 9 patients
- Memory enhancing effect of combined alcoholic extract of cedrus ceodara loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice
- Characterization of constipation in multiple system atrophy using Rome III diagnostic criteria
- Risk of Parkinson disease associated with prokinetics from Korean National Health Insurance service claims data
- Levodopa-induced dyskinesias impact patient’s quality of life in Parkinson’s disease in Singapore

**Topic: Behavior and Cognition**

- Relationship of performance in judgment tasks with executive function tasks and theory of mind in patients with Alzheimer’s disease and subjects with mild cognitive impairment
- Neuroprotective role of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats
  Speaker: Pardeep Kumar (New Dehli, India)
- Principles of non-pharmacological therapy in patients with Parkinson’s diseases
- Identifying the association of depression and distress in Pakistani patients diagnosed with parkinsonism syndrome
- Features of cognitive functions in parkinsonism
- The views of adults with Huntington’s disease on assisted dying in Uzbekistan: A qualitative exploration
- Cognitive dysfunction in multiple system atrophy-C
- Assessment of cognitive disorders in Parkinson’s disease (PD)
- New assessments of cognitive disorders in patients with parkinsonism in Uzbekistan

**Topic: Dystonia / Tremors**

- Bilateral pallidotomy in patients with generalized dystonia in Uzbekistan
Sensorimotor plasticity in writer’s cramp parallels clinical improvement after botulinum
toxin injections

Ultrasound echogenicity of the nuclei raphe as marker of depressive disorders in the
cervical dystonia

Orthostatic tremor complicated by spinal cord schwannoma

Topic: Chorea, Athetosis and Ballism

Case report: Chorea gravidarum persisting after delivery
Speaker: Karen Frei (Loma Linda, United States)

Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative
stress in a rat model of Huntington’s disease

Psychosocial impact of African families structure among patients with Huntington’s disease

Topic: Ataxias, Tics, and/or Myoclonus

Taking a step back to reframe the approach – an interesting case of tardive tourettism

Incidence of oculopalatal myoclonus in post-stroke patients

Clinical manifestations of SYNE1 mutation related cerebellar ataxia from Korea

The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid
conditions and secondary complications

A case of propriospinal myoclonus: secondary form or a sleep disorder?

Effects of different training programs on postural control and beta event-related
desynchronization in individuals with Parkinson’s disease: A pilot study

Delayed onset progressive spastic cerebellar ataxia and cerebellar atrophy as a delayed
complication of heat stroke

Topic: Gait and Other Movement Disorders

Influence of the level of cognitive impairment on gait parameters in older adults and
diagnosed with Parkinson’s disease

The prevalence of essential tremor in Edirne and its districts concomitant comorbid
conditions

A male patient showing abnormal gait, dysarthria and psychotic symptoms followed by
genetic diagnosis

Approaching health care shaped by Generational Expectations (The AGE Study):
Generational perspective related to time

A study of correlation between screening tools for cognitive decline and gait status using
three-dimensional gait analysis

A validity study of wearable accelerometer for estimating gait in Parkinson’s disease
Approaching health care shaped by Generational Expectations (The AGE Study): A perspective on technology and research

Global improvement and patient satisfaction: Results from a long-term, open-label, rollover study of valbenazine in tardive dyskinesia

Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations: Results from the BIPARK I study

Switch of double-blind opicapone, entacapone, or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I

**Late Breaking Abstracts**

- Screening of SCN11A in patients with essential tremor
- Generation of isogenic human G2019S Parkinson’s model
- Is there any difference between essential and dystonic head tremor?
- LRP10 subcellular localization in human iPS-derived dopaminergic neurons: Implications for LRP10 dysfunction in synucleinopathies
- PTRHD1 loss-of-function mutation in an African family with parkinsonism and intellectual disability

**Topic: Basic Neuroscience**

- Drug-Induced Parkinsonism as a risk factor for Parkinson’s disease: A cohort review from Uzbekistan
- Lead acute intoxication alters dopaminergic system and locomotor performance in Meriones shawi
- Assessment of antiparkinsonian activity by experimental way
- Experimental model of Parkinson’s syndrome in animals
- Tremorin model of Parkinson disease
- Methodical recommendation for experimental modeling of parkinsonian syndrome
- The experimental model of extrapyramidal disorders caused by reserpine
- L-theanine recues quinolinic acid induced motor dysfunction and striatal neurotoxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level
- Intranigral inoculation of Parkinson’s disease linked mutation G51D alpha-synuclein fibrils induces Lewy-like pathology in mice
- Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative diseases
- Aloe arborescens and Curcuma longa protect against acute copper exposure induced the neurobehavioral characteristics of Parkinson’s disease in rats
- Impaired dopaminergic and serotonergic innervations in thioacetamide induced acute hepatic encephalopathy may be linked to hypolocomotion
- Study on the operation time of deep brain stimulation for Parkinson’s disease
- 2014-2016 worldwide bibliometric snapshot of the scientific literature on Parkinson’s disease
Clinical correlations between Parkinson's disease and vascular parkinsonism: New retrospective review from Uzbekistan

The role of apoproteins in the development of Parkinson's disease

Combined administration of an A2A receptor antagonist and a 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson's disease

Prevention of Parkinson’s disease using natural biological additives

**Poster 15:00 - 20:00 Exhibition Forum 3**

**Topic: Imaging, Genetics and Biomarkers**

Cerebral microbleeds in dementia with Lewy bodies is not characteristic.

Assessment of clinic-biochemical features of Parkinson´s disease

Evaluation of the 70 kDa heat shock protein (Hsp70) plasma level in Parkinson’s disease and GBA-associated Parkinson’s disease patients

A rare fatal Familial parkinsonism in elderly with early respiratory failure

Application of convolutional neural networks in the diagnosis of Parkinson’s disease dementia based on magnetic resonance imaging

DAT scan abnormalities in juvenile Westphal variant of Huntington’s disease

Influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage

Association analysis of DRD2 rs2283265 and DRD1 rs4532 with Parkinson’s disease and Multiple system atrophy in a large Chinese population

Early brain metabolic changes in patients with Parkinson's disease and its correlation to the risk of falling

Spg 11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline

Speaker: Soham Desai (Anand, India)

Gene-lifestyle interactions in Parkinson’s disease

**Poster 15:00 - 20:00 Exhibition Forum 3**

**Topic: Parkinson Disease**

Influence of the stage in Parkinson´s Disease on the level of cognitive impairment in people over 65 years of age

A case report of psychosis in Parkinson disease treated with anticholinesterase drug

Use of safinamide in Parkinson’s disease patients over 70 years with dyskinesias and pharmacological psychosis

A non-motor symptom unheard of? Hearing loss in Mexican patients with Parkinson’s disease

Development of anti-Parkinsonism poly herbal sustained release formulation composed of potential traditional plant extracts
Microarray analysis upon a synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease

Postural instability in patients with Parkinson disease and its correction by balance therapy

Insomnia due to restlessness restricted to the perianal region in a patient with Parkinson’s disease

Worsening of dyskinesia following the change of peptic ulcer treatment in a patient with Parkinson’s disease under the Levodopa-Carbidopa Intestinal Gel infusion therapy

Investigation of sleep duration, sedentary behavior, and physical activity in idiopathic Parkinson Disease

Measurement of Parkinson’s disease patients functional ability before and after physiotherapy: a case series

Rotenone induced Parkinson’s disease model: Analysis of PARK2 and PINK1 genes expression

The late effects of traumatic brain injury- leading to Parkinson disease - A prospective study

Is restless legs syndrome (RLS), a prodromal feature of Parkinson’s disease (PD), associated to small fiber pathology?

Does the side of onset of motor symptoms in parkinsonian patients have an impact on the global clinical phenotype?

Instrumental evaluation of autonomic nervous system disfunction in idiopathic Parkinson’s disease

Effective rehabilitation program for Parkinson’s disease - from National Hospital Organization Japan

Interrelation between chronic pain syndrome and cognitive and affective disturbances in patients with Parkinson’s disease

Effect of ventricle size on development of freezing of gait in Parkinson’s disease

Non-motor symptoms of Parkinson’s disease: evaluation of urinary disorders

The impact of levodopa induced dyskinesia on the quality of life in Parkinson’s disease patients

Prevalence and associations for depression in patients with Parkinson’s disease: a Sri Lankan experience

Contribution of insomnia to the quality of life of patients in Parkinson’s disease

Metabolic and functional changes in the eye as a manifestation of the systemic neurodegeneration of parkinsonism

Acute lethargic state after abrupt apomorphine withdrawal in Parkinson’s disease

Evaluations of additive effect of two indigenous medicinal plants Cedrus Deodara and Mucuna pruriens towards the treatment of Parkinson’s disease

ON is not always ON: When non-motor fluctuations do not match motor fluctuation conditions

Trunk exercise program for Parkinson’s disease

The neuropsychiatric fluctuations scale for Parkinson’s disease: A pilot study

The impact of impulsivity on quality of life in drug-naive Parkinson’s disease

The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: Protocol of a randomized controlled trial

Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder

Investigation to expand application sites of rotigotine transdermal patch
The Polymorphism of SREBF1 Gene rs11868035 G/A is associated with susceptibility to Parkinson’s disease in a Chinese population

Quantitative keyboard measurement correlates with changes in subthalamic nucleus LFPs of Parkinson’s disease patients treated with dopaminergic medication better than UPDRS subscores

Brain-derived neutrophic factor and lipid profile in Parkinson’s disease

Fatigue in Parkinson’s disease: Correlates and its effects on ability of daily living

Thai bamboo dance: Improvements in gait, balance and foot clearance for Parkinson’s disease

Effectiveness and safety of continuous infusion of levodopa-carbidopa intestinal therapy for patients with advanced Parkinson’s disease: a single center experience

Russian validation study of the Berg Balance Scale

Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease trials (AT-HOME PD): Design of a long-term observational study

Neuroprotective effect of Naringin loaded solid lipid nanoparticles via induction of GDNF in MPP+ induced Parkinson’s disease in animal model

Decreased striatal dopamine and neuropsychiatric symptoms in patients with Parkinson’s disease

Patterns of movement disorders among HIV/AIDS patients: a cross sectional study

Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism

A phase 2A study of nilotinib in patients with advanced and early Parkinson’s disease study design

The comparison of gut biogeography of the gut bacterial microbiota in Parkinson’s disease

Clinical correlation of serum insulin-like growth factor-1 levels in patients with Parkinson’s disease and related disorders

Serum uric acid is associated with cognitive decline in de novo patients with Parkinson’s disease

Home mobility system for monitoring patients with Parkinson’s disease: validation with actigraphy

Can coenzyme Q10 and creatine slow the progress of Parkinson’s disease?

Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update

Neuropsychiatric and behavior changes in Parkinson’s disease patients with impulse control disorder after switching-off dopamine agonist by levodopa/carbidopa slow-release formulations

Microstructural changes in white and grey matter related to apathy, depression and anxiety in de novo Parkinson’s disease patients

Gait patterns in Parkinson’s disease with or without cognitive impairment

Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease

Socio-biological cues and saccade generation in Parkinson’s disease

Waking-day patterns of motor complications in Parkinson’s disease and the effect of ADS-5102

Effective diagnostic and treatment methods in vascular parkinsonism and Parkinson’s disease: Temporhhythmal correction

New clinical research: The role of OncoMarkers in Parkinson’s disease and vascular parkinsonism
A randomized, double blind, placebo controlled, single ascending dose, safety and pharmacokinetic/pharmacodynamic study of INP103 in the presence of benserazide, to L-dopa responsive Parkinson’s patients

Spectral fingerprints of impulse control disorders in Parkinson’s disease

Treatment approaches to pain in Parkinson disease: A systematic review

REM sleep behavior disorder in Parkinson disease: association with blunted heart rate variability on standing

Efficacy of incobotulinumtoxinA in patients with sialorrhoea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP)

Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhoea

Opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations: global impressions of change compared to placebo and entacapone

**Plenary Session**
15:30 - 17:00  
**Auditorium Lumière**

**Clinical Presentations of Basal Ganglia Disorders**
Chair: Erik Ch. Wolters (Amsterdam, Netherlands)  
Chair: Marie Vidailhet (Paris, France)

**Motor Manifestations of Basal Ganglia Disorders**  
Speaker: Hui-Fang Shang (Chengdu, Sichuan, China)  
15:30 - 16:00

**Behavioral Manifestations of Basal Ganglia Disorders**  
Speaker: Ergun Uc (Iowa City, United States)  
16:00 - 16:30

**Cognitive Dysfunction in Basal Ganglia Disorders**  
Speaker: Jennifer Goldman (Chicago, United States)  
16:30 - 17:00

**Plenary Session**
17:30 - 19:00  
**Auditorium Lumière**

**Opening Ceremony / Melvin Yahr Lectures**
Chair: Hubert Fernandez (Cleveland, United States)  
Chair: Elena Moro (Grenoble, France)

**The Brain and Passage of Time**  
Speaker: Yves Agid (Paris, France)  
17:30 - 17:45

**My Gut Reaction: The Story of Parkinson Disease from Mouth to the Colon**  
Speaker: Ronald Pfeiffer (Portland, United States)  
17:45 - 18:05

**Searching for the Holy Grail: Lessons learned from My Journey as a Clinician Scientist**  
Speaker: Michael Schwarzschild (Boston, United States)  
18:05 - 18:25
Monday, 20 August 2018

Plenary Session
08:00 - 10:00

Auditorium Lumière

Parkinsonism - Capturing the Giant
Chair: Elena Moro (Grenoble, France)
Chair: Daniel Truong (Fountain Valley, United States)

- **The Colorful Clinical Spectrum of Parkinsonism**
  Speaker: Roongroj Bhidayasiri (Bangkok, Thailand)
  Time: 08:00 - 08:30

- **Revisiting the Definition of Parkinson Disease**
  Speaker: Daniela Berg (Tuebingen, Germany)
  Time: 08:30 - 09:00

- **Victories and Losses in the Search for Elusive Parkinson Biomarkers**
  Speaker: Lorraine Kalia (Toronto, Canada)
  Time: 09:00 - 09:30

- **Environment and Genes: How They Create the Perfect Storm**
  Speaker: Caroline Tanner (San Francisco, United States)
  Time: 09:30 - 10:00

Poster
09:00 - 17:00

Exhibition Forum 3

**Topic: Deep Brain Stimulation and Functional Neurosurgery**

- Improvement of apraxia of eyelid opening in a patient with Parkinson’s disease following the change of the directional lead for subthalamic nucleus deep brain stimulation.

- Toe dystonia in Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation
  Speaker: Chloe Laureninc (Lyon, France)

- Long term outcome of the subthalamic nucleus DBS for advanced Parkinson’s disease: An eight years follow-up study in China

- The long-term development of excessive daytime sleepiness after subthalamic deep brain stimulation in patients with Parkinson’s disease

- Usefulness of directional deep brain stimulation in patients with movement disorders

- Predicting patient discharge disposition subsequent to deep brain stimulation surgery: A pilot study

- Meta-analysis of mortality following subthalamic and pallidal deep brain stimulation for patients with Parkinson’s disease

Poster
09:00 - 17:00

Exhibition Forum 3

**Topic: Other Parkinsonian Disorders**

- When PSP and CBD overlap: A case report

- Effects of green tea extract on Parkinsonism and related disorders; neuroleptic anxiety syndrome, growth & pain

- Features of the course of Parkinson’s disease in congenital anomalies of cerebral vessels

- Pharmacologic approaches in dementia with Lewy bodies: Lessons learned from a case series

- Levosulpride induced persistent movement disorders: case series
Single photon emission computer tomography in the differentiation of progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy

Movement disorders in bilateral striatopallidodentate calcinosis (Fahr’s syndrome): an analysis of 9 patients

Memory enhancing effect of combined alcoholic extract of cedrus ceodara loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice

Characterization of constipation in multiple system atrophy using Rome III diagnostic criteria

Risk of Parkinson disease associated with prokinetics from Korean National Health Insurance service claims data

Levodopa-induced dyskinesias impact patient’s quality of life in Parkinson’s disease in Singapore

**Topic: Behavior and Cognition**

Relationship of performance in judgment tasks with executive function tasks and theory of mind in patients with Alzheimer’s disease and subjects with mild cognitive impairment

Neuroprotective role of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats

Speaker: Pardeep Kumar (New Dehli, India)

Principles of non-pharmacological therapy in patients with Parkinson’s diseases

Identifying the association of depression and distress in Pakistani patients diagnosed with parkinsonism syndrome

Features of cognitive functions in parkinsonism

The views of adults with Huntington’s disease on assisted dying in Uzbekistan: A qualitative exploration

Cognitive dysfunction in multiple system atrophy-C

Assessment of cognitive disorders in Parkinson’s disease (PD)

New assessments of cognitive disorders in patients with parkinsonism in Uzbekistan

**Topic: Dystonia / Tremors**

Bilateral pallidotomy in patients with generalized dystonia in Uzbekistan

Sensorimotor plasticity in writer’s cramp parallels clinical improvement after botulinum toxin injections

Ultrasound echogenicity of the nuclei raphe as marker of depressive disorders in the cervical dystonia

Orthostatic tremor complicated by spinal cord schwannoma

**Topic: Chorea, Athetosis and Ballism**
Case report: Chorea gravidarum persisting after delivery
Speaker: Karen Frei (Loma Linda, United States)

Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

Psychosocial impact of African families structure among patients with Huntington’s disease

Topic: Ataxias, Tics, and/or Myoclonus

Taking a step back to reframe the approach – an interesting case of tardive tourettism

Incidence of oculopalatal myoclonus in post-stroke patients

Clinical manifestations of SYNE1 mutation related cerebellar ataxia from Korea

The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid conditions and secondary complications

A case of propriospinal myoclonus: secondary form or a sleep disorder?

Effects of different training programs on postural control and beta event-related desynchronization in individuals with Parkinson’s disease: A pilot study

Delayed onset progressive spastic cerebellar ataxia and cerebellar atrophy as a delayed complication of heat stroke

Topic: Gait and Other Movement Disorders

Influence of the level of cognitive impairment on gait parameters in older adults and diagnosed with Parkinson’s disease

The prevalence of essential tremor in Edirne and its districts concomitant comorbid conditions

A male patient showing abnormal gait, dysarthria and psychotic symptoms followed by genetic diagnosis

Approaching health care shaped by Generational Expectations (The AGE Study): Generational perspective related to time

A study of correlation between screening tools for cognitive decline and gait status using three-dimensional gait analysis

A validity study of wearable accelerometer for estimating gait in Parkinson’s disease

Approaching health care shaped by Generational Expectations (The AGE Study): A perspective on technology and research

Global improvement and patient satisfaction: Results from a long-term, open-label, rollover study of valbenazine in tardive dyskinesia

Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations: Results from the BIPARK I study

Switch of double-blind opicapone, entacapone, or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I
Late Breaking Abstracts

- Screening of SCN11A in patients with essential tremor
- Generation of isogenic human G2019S Parkinson’s model
- Is there any difference between essential and dystonic head tremor?
- LRP10 subcellular localization in human iPS-derived dopaminergic neurons: Implications for LRP10 dysfunction in synucleinopathies
- PTRHD1 loss-of-function mutation in an African family with parkinsonism and intellectual disability

Topic: Basic Neuroscience

- Drug-Induced Parkinsonism as a risk factor for Parkinson’s disease: A cohort review from Uzbekistan
- Lead acute intoxication alters dopaminergic system and locomotor performance in Meriones shawi
- Assessment of antiparkinsonian activity by experimental way
- Experimental model of Parkinson’s syndrome in animals
- Tremorin model of Parkinson disease
- Methodical recommendation for experimental modeling of parkinsonian syndrome
- The experimental model of extrapyramidal disorders caused by reserpine
- L-theanine rescues quinolinic acid induced motor dysfunction and striatal neurotoxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level
- Intranigral inoculation of Parkinson’s disease linked mutation G51D alpha-synuclein fibrils induces Lewy-like pathology in mice
- Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative diseases
- Aloe arborescens and Curcuma longa protect against acute copper exposure induced the neurobehavioral characteristics of Parkinson’s disease in rats
- Impaired dopaminergic and serotonergic innervations in thioacetamide induced acute hepatic encephalopathy may be linked to hypolocomotion
- Study on the operation time of deep brain stimulation for Parkinson’s disease
- 2014-2016 worldwide bibliometric snapshot of the scientific literature on Parkinson’s disease
- Clinical correlations between Parkinson’s disease and vascular parkinsonism: New retrospective review from Uzbekistan
- The role of apoproteins in the development of Parkinson’s disease
- Combined administration of an A2A receptor antagonist and a 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
- Prevention of Parkinson’s disease using natural biological additives
**Topic: Parkinson Disease**

Influence of the stage in Parkinson’s Disease on the level of cognitive impairment in people over 65 years of age

A case report of psychosis in Parkinson disease treated with anticholinesterase drug

Use of safinamide in Parkinson’s disease patients over 70 years with dyskinesias and pharmacological psychosis

A non-motor symptom unheard of? Hearing loss in Mexican patients with Parkinson’s disease

Development of anti-Parkinsonism poly herbal sustained release formulation composed of potential traditional plant extracts

Microarray analysis upon a synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease

Postural instability in patients with Parkinson disease and its correction by balance therapy

Insomnia due to restlessness restricted to the perianal region in a patient with Parkinson’s disease

Worsening of dyskinesia following the change of peptic ulcer treatment in a patient with Parkinson’s disease under the Levodopa-Carbidopa Intestinal Gel infusion therapy

Investigation of sleep duration, sedentary behavior, and physical activity in idiopathic Parkinson Disease

Measurement of Parkinson’s disease patients functional ability before and after physiotherapy: a case series

Rotenone induced Parkinson’s disease model: Analysis of PARK2 and PINK1 genes expression

The late effects of traumatic brain injury- leading to Parkinson disease - A prospective study

Is restless legs syndrome (RLS), a prodromal feature of Parkinson’s disease (PD), associated to small fiber pathology?

Does the side of onset of motor symptoms in parkinsonian patients have an impact on the global clinical phenotype?

Instrumental evaluation of autonomic nervous system disfunction in idiopathic Parkinson’s disease

Effective rehabilitation program for Parkinson’s disease - from National Hospital Organization Japan

Interrelation between chronic pain syndrome and cognitive and affective disturbances in patients with Parkinson’s disease

Effect of ventricle size on development of freezing of gait in Parkinson’s disease

Non-motor symptoms of Parkinson’s disease: evaluation of urinary disorders

The impact of levodopa induced dyskinesia on the quality of life in Parkinson’s disease patients

Prevalence and associations for depression in patients with Parkinson’s disease: a Sri Lankan experience

Contribution of insomnia to the quality of life of patients in Parkinson’s disease

Metabolic and functional changes in the eye as a manifestation of the systemic neurodegeneration of parkinsonism

Acute lethargic state after abrupt apomorphine withdrawal in Parkinson’s disease
Evaluations of additive effect of two indigenous medicinal plants Cedrus Deodara and Mucuna pruriens towards the treatment of Parkinson’s disease

ON is not always ON: When non-motor fluctuations do not match motor fluctuation conditions

Trunk exercise program for Parkinson’s disease

The neuropsychiatric fluctuations scale for Parkinson’s disease: A pilot study

The impact of impulsivity on quality of life in drug-naive Parkinson’s disease

The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: Protocol of a randomized controlled trial

Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder

Investigation to expand application sites of rotigotine transdermal patch

The Polymorphism of SREBF1 Gene rs11868035 G/A is associated with susceptibility to Parkinson’s disease in a Chinese population

Quantitative keyboard measurement correlates with changes in subthalamic nucleus LFPs of Parkinson’s disease patients treated with dopaminergic medication better than UPDRS subscores

Brain-derived neutrophic factor and lipid profile in Parkinson’s disease

Fatigue in Parkinson’s disease: Correlates and its effects on ability of daily living

Thai bamboo dance: Improvements in gait, balance and foot clearance for Parkinson’s disease

Effectiveness and safety of continuous infusion of levodopa-carbidopa intestinal therapy for patients with advanced Parkinson’s disease: a single center experience

Russian validation study of the Berg Balance Scale

Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease trials (AT-HOME PD): Design of a long-term observational study

Neuroprotective effect of Naringin loaded solid lipid nanoparticles via induction of GDNF in MPP+ induced Parkinson’s disease in animal model

Decreased striatal dopamine and neuropsychiatric symptoms in patients with Parkinson’s disease

Patterns of movement disorders among HIV/AIDS patients: a cross sectional study

Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism

A phase 2A study of nilotinib in patients with advanced and early Parkinson’s disease study design

The comparison of gut biogeography of the gut bacterial microbiota in Parkinson’s disease

Clinical correlation of serum insulin-like growth factor-1 levels in patients with Parkinson’s disease and related disorders

Serum uric acid is associated with cognitive decline in de novo patients with Parkinson’s disease

Home mobility system for monitoring patients with Parkinson’s disease: validation with actigraphy

Can coenzyme Q10 and creatine slow the progress of Parkinson’s disease?

Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Neuropsychiatric and behavior changes in Parkinson´s disease patients with impulse control disorder after switching-off dopamine agonist by levodopa/carbidopa slow-release formulations

Microstructural changes in white and grey matter related to apathy, depression and anxiety in de novo Parkinson’s disease patients

Gait patterns in Parkinson’s disease with or without cognitive impairment

Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease

Socio-biological cues and saccade generation in Parkinson’s disease

Waking-day patterns of motor complications in Parkinson’s disease and the effect of ADS-5102

Effective diagnostic and treatment methods in vascular parkinsonism and Parkinson´s disease: Temporhythmal correction

New clinical research: The role of OncoMarkers in Parkinson´s disease and vascular parkinsonism

A randomized, double blind, placebo controlled, single ascending dose, safety and pharmacokinetic/pharmacodynamic study of INP103 in the presence of benserazide, to L-dopa responsive Parkinson’s patients

Spectral fingerprints of impulse control disorders in Parkinson’s disease

Treatment approaches to pain in Parkinson disease: A systematic review

REM sleep behavior disorder inparkinson disease: association with blunted heart rate variability on standing

Efficacy of incobotulinumtoxinA in patients with sialorrhoea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP)

Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhoea

Opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations: global impressions of change compared to placebo and entacapone

**Topic: Imaging, Genetics and Biomarkers**

Cerebral microbleeds in dementia with Lewy bodies is not characteristic.

Assessment of clinic-biochemical features of Parkinson´s disease

Evaluation of the 70 kDa heat shock protein (Hsp70) plasma level in Parkinson’s disease and GBA-associated Parkinson’s disease patients

A rare fatal Familial parkinsonism in elderly with early respiratory failure

Application of convolutional neural networks in the diagnosis of Parkinson’s disease dementia based on magnetic resonance imaging

DAT scan abnormalities in juvenile Westphal variant of Huntington’s disease

Influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage

Association analysis of DRD2 rs2283265 and DRD1 rs4532 with Parkinson´s disease and Multiple system atrophy in a large Chinese population

Early brain metabolic changes in patients with Parkinson’s disease and its correlation to the risk of falling
Spg 11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline

Speaker: Soaham Desai (Anand, India)

Gene-lifestyle interactions in Parkinson’s disease

Coffee with the Professor
10:00 - 10:30 Foyer Forum

Coffee with the Professor 1
Chair: Kailash Bhatia (London, United Kingdom)

Parallel Tracks
10:30 - 12:00 Auditorium Lumière

Imaging and Pathology in Parkinsonian Disorders
Chair: Ioannis Isaias (Wuerzburg, Germany)
Chair: Peter Riederer (Wuerzburg, Germany)

Focus on Morphological Imaging in Parkinsonian Disorders
Speaker: Stephane Lehericy (Paris, France)

Focus on Functional Imaging in Parkinsonian Disorders
Speaker: Stephane Thobois (Lyon, France)

Current Pathological Understanding of Parkinsonian Disorders
Speaker: Peter Riederer (Wuerzburg, Germany)

Parallel Tracks
10:30 - 12:00 Forum 1

Other Diagnostic Tools in Parkinsonian Disorders
Chair: Raymond Rosales (Quezon City, Philippines)

How Sleep Studies are Shedding Light on our Understanding of Parkinsonian Disorders
Speaker: Ronald Postuma (Montreal, Canada)

Can the Gut be the Missing Piece in Uncovering PD Pathogenesis?
Speaker: Pascal Derkinderen (Nantes, France)

Acknowledging the Giant Elephant: The Utility of Cognitive and Behavioral Assessments in PD
Speaker: Jaime Kulisevsky (Barcelona, Spain)

Skills Workshops
10:30 - 12:00 Forum 2

Examining the Parkinsonian Patient
Chair: Shinsuke Fujioka (Fukuoka, Japan)

How To Examine a Parkinsonian Patient Like An Expert
Speaker: Leonard Verhagen (Chicago, United States)
Recognizing Red Flags that Suggest Parkinson-Plus Syndromes 11:00 - 11:30
Speaker: Roongroj Bhidayasiri (Bangkok, Thailand)

Learning from Experience: Pitfalls and Misconceptions in Parkinsonian Presentations 11:30 - 12:00
Speaker: Alberto Albanese (Milan, Italy)

OP-01, Oral Poster Session I - Behavior and Cognition, Deep Brain Stimulation
Moderator: Daniel Weintraub (Philadelphia, United States)
Moderator: Raja Mehanna (Houston, United States)

Freezing of gait in Parkinson’s disease: Is it just a motor problem or more?
Speaker: Moulika Mandal (Mumbai, India)

Cognitive stimulation is beneficial for individuals with Parkinson’s disease dementia living in long-term care: A randomized crossover pilot study

Cognition in subjects with REM sleep behavior disorder and cumulative signs of prodromal Parkinson’s disease

Visual spatial working memory and executive function deficits in single- versus multiple-domain amnestic mild cognitive impairment: a combined ERP and sLORETA study

Cognitive and histopathological phenotypes in new rat models of cortical synucleinopathy
Speaker: M. Angela Cenci (Lund, Sweden)

Association between post-operative delirium and Parkinson disease following common US surgical procedures

Cortical 123I-FP-CIT binding deficits are associated with mild cognitive impairment in Parkinson’s disease

Subthalamic deep brain stimulation for advanced Parkinson’s disease beyond the 5-year follow-up

Deep brain stimulation of the nucleus basalis of Meynert as a treatment for Parkinson’s Disease Dementia: A systematic review of animal studies

Long-term effect of subthalamic deep brain stimulation in young- and late-onset Parkinson’s disease: 10-year follow-up study

Bilateral GPI DBS improves medically intractable postural and kinetic tremor in patients with Parkinson’s disease

Non-motor symptoms in dystonia patients and influence of deep brain stimulation and botulinum toxin on them

The subthalamic nucleus activity at gait initiation in Parkinson’s disease

Long-term clinical outcome of deep brain stimulation for PKAN syndrome

Finding ways to improve axial symptoms in patients with chronic STN DBS for Parkinson’s disease

Battery longevity of neurostimulators in Parkinson-disease: A historic cohort study

Suicide after STN-DBS in Parkinson’ disease: who, when and how to prevent?
Corporate Session 1: Debating OFF Phenomenon in Parkinson Disease: Lessons Learned after 40 Years - Supported by an unrestricted grant of Sunovion

Chair: Hubert Fernandez (Cleveland, United States)

- Why debating OFF phenomenon remains relevant today as it was 40 years ago
  Speaker: Hubert Fernandez (Cleveland, United States) 12:15 - 12:35

- Position 1: We have made great strides in addressing OFF phenomenon in PD; it is time to move on
  Speaker: Tanya Simuni (Chicago, United States) 12:35 - 12:55

- Position 2: We have a long way to go in understanding and treating OFF phenomenon in PD
  Speaker: Alberto Espay (Cincinnati, United States) 12:55 - 13:15

Panel Discussion 13:15 - 13:45

Corporate Session 2: New Trends and Horizons in DBS - Supported by an unrestricted grant of Boston Scientific SAS

Chair: Elena Moro (Grenoble, France)
Chair: Stephane Thobois (Lyon, France)

- Is there potential to expand the capabilities of DBS with Directionality? Surgical Perspective
  Speaker: Stephan Chabardes (Grenoble, France) 12:15 - 12:35

- Short Pulse Width: Pathway Selectivity and Therapeutic Window Outcomes
  Speaker: Vish Dayal (London, United Kingdom) 12:35 - 12:55

- Directionality - Programming Guidelines & Workflow Perspective: Role of Visualization
  Speaker: Jens Volkmann (Wuerzburg, Germany) 12:55 - 13:15

Plenary Session
Auditorium Lumière

PD and Parkinson-Plus Therapy - Current Treatments for PD and Parkinson-Plus Syndromes

Chair: Tanya Simuni (Chicago, United States)
Chair: Franck Durif (Clermont Ferrand, France)

- Current Approach to PD Motor Treatment: An Emerging Consensus?
  Speaker: Marcelo Merello (Buenos Aires, Argentina) 13:45 - 14:15

- Addressing the Behavioral and Cognitive Complications in PD
  Speaker: Irena Rektorova (Brno, Czech Republic) 14:15 - 14:45

- Progress in the Treatment of Parkinson-Plus Syndromes
  Speaker: Irene Litvan (San Diego, United States) 14:45 - 15:15
Coffee with the Professor
15:15 - 15:45
Foyer Forum

Coffee with the Professor 2
Chair: Caroline Tanner (San Francisco, United States)

Parallel Tracks
15:45 - 17:15
Auditorium Lumière

Challenging Features in Parkinsonian Disorders
Chair: Pramod Pal (Bengaluru, Karnataka, India)

Preventing Falls and Fractures: The Approach to Freezing and Gait Instability
Speaker: Ioannis Isaias (Wuerzburg, Germany) 15:45 - 16:15

A Deep Dive into the Sea of Dysautonomic Complication in PD
Speaker: Paola Sandroni (New York, United States) 16:15 - 16:45

Sensible Strategies for Sleep Dysfunction in the PD Patient
Speaker: Christian Baumann (Zurich, Switzerland) 16:45 - 17:15

Parallel Tracks
15:45 - 17:15
Forum 1

Alternative and Palliative Therapies in Parkinson Disease
Chair: Hrishikesh Kumar (West Bengal, India)

The Evidence of Exercise in Enhancing the Management of PD
Speaker: Bettina Debu (Grenoble, France) 15:45 - 16:15

The Ever Expanding Role of Botulinum Toxins in Parkinsonian Disorders
Speaker: Mark Lew (Los Angeles, United States) 16:15 - 16:45

Completing the Chapter of Care: End of Life Issues in PD
Speaker: Miguel Coelho (Lisbon, Portugal) 16:45 - 17:15

Parallel Tracks
15:45 - 17:15
Forum 2

Gastrointestinal Issues in Parkinson Disease supported by Merz Pharmaceuticals GmbH with an unrestricted grant
Chair: Ronald Pfeiffer (Portland, United States)

How Relevant is Nutrition in PD Care and Management?
Speaker: Emanuele Cerada (Pavia, Italy) 15:45 - 16:15

Upper Gastrointestinal Challenges in Parkinson Disease
Speaker: Heinz Reichmann (Dresden, Germany) 16:15 - 16:45

Lower Gastrointestinal Challenges in Parkinson Disease
Speaker: Ronald Pfeiffer (Portland, United States) 16:45 - 17:15
OP-02, Oral Poster Session II - Ataxias, Tics, and/or Myoclonus, Dystonia, Gait and Other MD, Tremors

Moderator: Maria Stamelou (Athens, Greece)
Moderator: Diego Torres-Russotto (Omaha, United States)

- Frequencies, genetic, clinical and radiologic characterization of spinocerebellar ataxia in Korea
- MiRNAs influence Insulin/diabetes pathways to exacerbate the clinical severity in Spinocerebellar ataxia type-2
- Subcortical brain areas correlate genetic characteristics in spinocerebellar ataxia type 2 patients
- Clinical and genetic aspects of Huntington’s disease in 1 Malian families: The largest cohort genetically confirmed in Sub-Saharan Africa
- Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study
- Intero- and exteroceptive mirroring and overflow movements are useful in assessing writer’s cramp
- Hyperkinetic movement disorders induced by mirtazapine: unusual case report and clinical analysis of reported cases
- Deep brain stimulation parameters for dystonia: A systematic review
- Approach to health care shaped by Generational Expectations (the AGE study): Patients’ preferences for healthcare providers
- Effects of long-term valbenazine on tardive dyskinesia and patient-reported outcomes: Results from the KINECT 4 study
- The neural mechanism of freezing of gait in patients with Parkinson’s disease

Coffee with the Professor
17:15 - 17:45

Coffee with the Professor 3
Chair: Vincenzo Bonifati (Rotterdam, Netherlands)

Parallel Tracks
17:45 - 19:15

Parkinson Disease Care in Unique Settings
Chair: Yaroslau Compta Hirnyi (Barcelona, Spain)

- When Time is of the Essence: Managing Care in Emergency Situations
  Speaker: Pramod Pal (Bengaluru, Karnataka, India)
  17:45 - 18:15

- What To Do When Your Parkinson Patient Has To Undergo Surgery: From Pre- to Post-Operative State
  Speaker: Leonard Verhagen (Chicago, United States)
  18:15 - 18:45

- Are We Really Ready for Telemedicine and Distance Health?
  Speaker: Mark Guttman (Toronto, Canada)
  18:45 - 19:15
**Practical Issues on Deep Brain Stimulation Therapy for PD**

**Chair:** Elena Moro (Grenoble, France)

**Patient Selection: Combining Evidence with Experience**  
17:45 - 18:15  
Speaker: Jens Volkmann (Wuerzburg, Germany)

**Pearls and Pitfalls in DBS Programming**  
18:15 - 18:45  
Speaker: Joohi Jimenez-Shahed (Houston, United States)

**When Things Don’t Go As Planned: Troubleshooting in DBS**  
18:45 - 19:15  
Speaker: Raja Mehanna (Houston, United States)

**Pumps and Infusions in Parkinson Disease**

**Chair:** Thomas Mueller (Berlin, Germany)

**Apomorphine Infusion: Setting up and Troubleshooting**  
17:45 - 18:15  
Speaker: Marcelo Merello (Buenos Aires, Argentina)

**Levodopa Intestinal Gel: Setting up and Troubleshooting**  
18:15 - 18:45  
Speaker: David Grabli (Paris, France)

**Which Pump to Use? Optimal Patient Selection for Each Advanced Therapy**  
18:45 - 19:15  
Speaker: Emmanuel Flamand-Roze (Paris, France)

**OP-03, Oral Poster Session III - Parkinson Disease**

**Nilotinib increases dopamine metabolism and reduces oligomeric:total alpha-synuclein ratio in Parkinson’s disease**

**Clinical subtypes of excessive daytime sleepiness in Parkinson’s disease**

**Neuroprotective effects of Ethnodyn Neuro® (SNC-1), a natural product used in ayurvedic traditional medicine, on in vitro models of Parkinson’s disease.**

**Propensity of Mucuna Pruriens to offset rotenone-induced biochemical, behavioral and oxidative dysfunctions in mice: Implications for Parkinson’s disease**

**Effect of Tai Chi exercise to reduce falls and improve balance performance in Parkinson’s disease: A meta-analysis**

**Is Parkinson’s disease with history of agent orange exposure different from idiopathic Parkinson’s disease?**

**α-Synuclein induced dopaminergic neurons mitochondrial dysfunction via cytochrome c oxidase subunit 2**

**Dopaminergic treatment and speech in Parkinson’s disease: Acoustic analysis and correlation with motor features and dyskinetias**

**Video game-based dexterity training in patients with Parkinson’s disease: a pilot feasibility study**

**PROtein, LEucine And vitamin D Enhancing Rehabilitation (PRO-LEADER) in patients with Parkinson’s disease or parkinsonism: An RCT**
Parkinson's disease: Social determinants of quality of life of patients in the central belt of Ghana

Exploration of the regulation of miR-4639-5p expression and its role in the pathogenesis of Parkinson's disease

Biochemical studies in the brain of transgenic drosophila as a model of Parkinson's disease treated by ropinirole silver nanocomposite (RAgNC)

Rifampicin inhibits rotenone-induced inflammation by improving lysosomal function and autophagic flux in microglia

Effects of transcranial magnetic stimulation on hypokinetic dysarthria in Parkinson's disease

Bradykinesia assessment using evolutionary algorithms in Parkinson's disease: Clinical validation

Genomic variants associated with cognitive impairment in Parkinson's disease

Tear proteins as possible biomarkers for Parkinson's disease
Hyperkinetic Disorders I - The Three Other Giants: Chorea, Tics and Dystonia

Chair: Raymond Rosales (Quezon City, Philippines)
Chair: Vincenzo Bonifati (Rotterdam, Netherlands)

Meeting The Diverse Family of Hyperkinetic Disorders 08:00 - 08:30
Speaker: Kailash Bhatia (London, United Kingdom)

Greatest Lessons Learned in Huntington’s Disease 08:30 - 09:00
Speaker: Tiago Mestre (Ottawa, Canada)

Tics, Tourette's and Stereotypies: Birds of the Same Feather that Do Not Flock Together 09:00 - 09:30
Speaker: Davide Martino (Calgary, Canada)

The Colorful Spectrum of Dystonia and the Evolution of its Classification 09:30 - 10:00
Speaker: Marie Vidailhet (Paris, France)

Poster
09:00 - 17:00
Exhibition Forum 3

Topic: Deep Brain Stimulation and Functional Neurosurgery

Improvement of apraxia of eyelid opening in a patient with Parkinson’s disease following the change of the directional lead for subthalamic nucleus deep brain stimulation.

Toe dystonia in Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation
Speaker: Chloe Laurencin (Lyon, France)

Long term outcome of the subthalamic nucleus DBS for advanced Parkinson’s disease: An eight years follow-up study in China

The long-term development of excessive daytime sleepiness after subthalamic deep brain stimulation in patients with Parkinson’s disease

Usefulness of directional deep brain stimulation in patients with movement disorders

Predicting patient discharge disposition subsequent to deep brain stimulation surgery: A pilot study

Meta-analysis of mortality following subthalamic and pallidal deep brain stimulation for patients with Parkinson’s disease

Poster
09:00 - 17:00
Exhibition Forum 3

Topic: Other Parkinsonian Disorders

When PSP and CBD overlap: A case report

Effects of green tea extract on Parkinsonism and related disorders; neuroleptic anxiety syndrome, growth & pain

Features of the course of Parkinson’s disease in congenital anomalies of cerebral vessels

Pharmacologic approaches in dementia with Lewy bodies: Lessons learned from a case series

Levosulpride induced persistent movement disorders: case series
Single photon emission computer tomography in the differentiation of progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy

Movement disorders in bilateral striatopallidodentate calcinosis (Fahr’s syndrome): an analysis of 9 patients

Memory enhancing effect of combined alcoholic extract of cedrus ceodara loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice

Characterization of constipation in multiple system atrophy using Rome III diagnostic criteria

Risk of Parkinson disease associated with prokinetics from Korean National Health Insurance service claims data

Levodopa-induced dyskinesias impact patient’s quality of life in Parkinson’s disease in Singapore

---

**Topic: Behavior and Cognition**

Relationship of performance in judgment tasks with executive function tasks and theory of mind in patients with Alzheimer’s disease and subjects with mild cognitive impairment

Neuroprotective role of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats

Speaker: Pardeep Kumar (New Dehli, India)

Principles of non-pharmacological therapy in patients with Parkinson’s diseases

Identifying the association of depression and distress in Pakistani patients diagnosed with parkinsonism syndrome

Features of cognitive functions in parkinsonism

The views of adults with Huntington’s disease on assisted dying in Uzbekistan: A qualitative exploration

Cognitive dysfunction in multiple system atrophy-C

Assessment of cognitive disorders in Parkinson’s disease (PD)

New assessments of cognitive disorders in patients with parkinsonism in Uzbekistan

---

**Topic: Dystonia / Tremors**

Bilateral pallidotomy in patients with generalized dystonia in Uzbekistan

Sensorimotor plasticity in writer’s cramp parallels clinical improvement after botulinum toxin injections

Ultrasound echogenicity of the nuclei raphe as marker of depressive disorders in the cervical dystonia

Orthostatic tremor complicated by spinal cord schwannoma

---

**Topic: Chorea, Athetosis and Ballism**
Case report: Chorea gravidarum persisting after delivery
Speaker: Karen Frei (Loma Linda, United States)

Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington´s disease

Psychosocial impact of African families structure among patients with Huntington´s disease

**Topic: Ataxias, Tics, and/or Myoclonus**

- Taking a step back to reframe the approach – an interesting case of tardive tourettism
- Incidence of oculopalatal myoclonus in post-stroke patients
- Clinical manifestations of SYNE1 mutation related cerebellar ataxia from Korea
- The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid conditions and secondary complications
- A case of propriospinal myoclonus: secondary form or a sleep disorder?
- Effects of different training programs on postural control and beta event-related desynchronization in individuals with Parkinson’s disease: A pilot study
- Delayed onset progressive spastic cerebellar ataxia and cerebellar atrophy as a delayed complication of heat stroke

**Topic: Gait and Other Movement Disorders**

- Influence of the level of cognitive impairment on gait parameters in older adults and diagnosed with Parkinson´s disease
- The prevalence of essential tremor in Edirne and its districts concomitant comorbid conditions
- A male patient showing abnormal gait, dysarthria and psychotic symptoms followed by genetic diagnosis
- Approaching health care shaped by Generational Expectations (The AGE Study): Generational perspective related to time
- A study of correlation between screening tools for cognitive decline and gait status using three-dimensional gait analysis
- A validity study of wearable accelerometer for estimating gait in Parkinson’s disease
- Approaching health care shaped by Generational Expectations (The AGE Study): A perspective on technology and research
- Global improvement and patient satisfaction: Results from a long-term, open-label, rollover study of valbenazine in tardive dyskinesia
- Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations: Results from the BIPARK I study
- Switch of double-blind opicapone, entacapone, or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I
Late Breaking Abstracts

Screening of SCN11A in patients with essential tremor

Generation of isogenic human G2019S Parkinson’s model

Is there any difference between essential and dystonic head tremor?

LRP10 subcellular localization in human IPS-derived dopaminergic neurons: Implications for LRP10 dysfunction in synucleinopathies

PTRHD1 loss-of-function mutation in an African family with parkinsonism and intellectual disability

Topic: Basic Neuroscience

Drug-Induced Parkinsonism as a risk factor for Parkinson’s disease: A cohort review from Uzbekistan

Lead acute intoxication alters dopaminergic system and locomotor performance in Meriones shawi

Assessment of antiparkinsonian activity by experimental way

Experimental model of Parkinson’s syndrome in animals

Tremorin model of Parkinson disease

Methodical recommendation for experimental modeling of parkinsonian syndrome

The experimental model of extrapyramidal disorders caused by reserpine

L-theanine recues quinolinic acid induced motor dysfunction and striatal neurotoxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level

Intranigral inoculation of Parkinson’s disease linked mutation G51D alpha-synuclein fibrils induces Lewy-like pathology in mice

Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative diseases

Aloe arborescens and Curcuma longa protect against acute copper exposure induced the neurobehavorial characteristics of Parkinson’s disease in rats

Impaired dopaminergic and serotonergic innervations in thioacetamide induced acute hepatic encephalopathy may be linked to hypolocomotion

Study on the operation time of deep brain stimulation for Parkinson’s disease

2014-2016 worldwide bibliometric snapshot of the scientific literature on Parkinson’s disease

Clinical correlations between Parkinson’s disease and vascular parkinsonism: New retrospective review from Uzbekistan

The role of apoproteins in the development of Parkinson’s disease

Combined administration of an A2A receptor antagonist and a 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease

Prevention of Parkinson’s disease using natural biological additives
**Topic: Imaging, Genetics and Biomarkers**

Cerebral microbleeds in dementia with Lewy bodies is not characteristic.

Assessment of clinic-biochemical features of Parkinson´s disease

Evaluation of the 70 kDa heat shock protein (Hsp70) plasma level in Parkinson’s disease and GBA-associated Parkinson’s disease patients

A rare fatal Familial parkinsonism in elderly with early respiratory failure

Application of convolutional neural networks in the diagnosis of Parkinson’s disease dementia based on magnetic resonance imaging

DAT scan abnormalities in juvenile Westphal variant of Huntington’s disease

Influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage

Association analysis of DRD2 rs2283265 and DRD1 rs4532 with Parkinson´s disease and Multiple system atrophy in a large Chinese population

Early brain metabolic changes in patients with Parkinson’s disease and its correlation to the risk of falling

Spg 11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline

Speaker: Soham Desai (Anand, India)

Gene-lifestyle interactions in Parkinson’s disease

**Topic: Parkinson Disease**

Influence of the stage in Parkinson’s Disease on the level of cognitive impairment in people over 65 years of age

A case report of psychosis in Parkinson disease treated with anticholinesterase drug

Use of safinamide in Parkinson’s disease patients over 70 years with dyskinesias and pharmacological psychosis

A non-motor symptom unheard of? Hearing loss in Mexican patients with Parkinson’s disease

Development of anti-Parkinsonism poly herbal sustained release formulation composed of potential traditional plant extracts

Microarray analysis upon a synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease

Postural instability in patients with Parkinson disease and its correction by balance therapy

Insomnia due to restlessness restricted to the perianal region in a patient with Parkinson’s disease

Worsening of dyskinesia following the change of peptic ulcer treatment in a patient with Parkinson’s disease under the Levodopa-Carbidopa Intestinal Gel infusion therapy

Investigation of sleep duration, sedentary behavior, and physical activity in idiopathic Parkinson Disease
Measurement of Parkinson’s disease patients functional ability before and after physiotherapy: a case series

Rotenone induced Parkinson’s disease model: Analysis of PARK2 and PINK1 genes expression

The late effects of traumatic brain injury- leading to Parkinson disease - A prospective study

Is restless legs syndrome (RLS), a prodromal feature of Parkinson’s disease (PD), associated to small fiber pathology?

Does the side of onset of motor symptoms in parkinsonian patients have an impact on the global clinical phenotype?

Instrumental evaluation of autonomic nervous system disfunction in idiopathic Parkinson’s disease

Effective rehabilitation program for Parkinson’s disease - from National Hospital Organization Japan

Interrelation between chronic pain syndrome and cognitive and affective disturbances in patients with Parkinson’s disease

Effect of ventricle size on development of freezing of gait in Parkinson’s disease

Non-motor symptoms of Parkinson’s disease: evaluation of urinary disorders

The impact of levodopa induced dyskinesia on the quality of life in Parkinson’s disease patients

Prevalence and associations for depression in patients with Parkinson’s disease: a Sri Lankan experience

Contribution of insomnia to the quality of life of patients in Parkinson’s disease

Metabolic and functional changes in the eye as a manifestation of the systemic neurodegeneration of parkinsonism

Acute lethargic state after abrupt apomorphine withdrawal in Parkinson’s disease

Evaluations of additive effect of two indigenous medicinal plants Cedrus Deodara and Mucuna pruriens towards the treatment of Parkinson’s disease

ON is not always ON: When non-motor fluctuations do not match motor fluctuation conditions

Trunk exercise program for Parkinson’s disease

The neuropsychiatric fluctuations scale for Parkinson’s disease: A pilot study

The impact of impulsivity on quality of life in drug-naive Parkinson’s disease

The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: Protocol of a randomized controlled trial

Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder

Investigation to expand application sites of rotigotine transdermal patch

The Polymorphism of SREBF1 Gene rs11868035 G/A is associated with susceptibility to Parkinson’s disease in a Chinese population

Quantitative keyboard measurement correlates with changes in subthalamic nucleus LFPs of Parkinson’s disease patients treated with dopaminergic medication better than UPDRS subscores

Brain-derived neutrophic factor and lipid profile in Parkinson’s disease

Fatigue in Parkinson’s disease: Correlates and its effects on ability of daily living

Thai bamboo dance: Improvements in gait, balance and foot clearance for Parkinson’s disease
Effectiveness and safety of continuous infusion of levodopa-carbidopa intestinal therapy for patients with advanced Parkinson’s disease: a single center experience

Russian validation study of the Berg Balance Scale

Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease trials (AT-HOME PD): Design of a long-term observational study

Neuroprotective effect of Naringin loaded solid lipid nanoparticles via induction of GDNF in MPP+ induced Parkinson’s disease in animal model

Decreased striatal dopamine and neuropsychiatric symptoms in patients with Parkinson’s disease

Patterns of movement disorders among HIV/AIDS patients: a cross sectional study

Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism

A phase 2A study of nilotinib in patients with advanced and early Parkinson’s disease study design

The comparison of gut biogeography of the gut bacterial microbiota in Parkinson’s disease

Clinical correlation of serum insulin-like growth factor-1 levels in patients with Parkinson’s disease and related disorders

Serum uric acid is associated with cognitive decline in de novo patients with Parkinson’s disease

Home mobility system for monitoring patients with Parkinson’s disease: validation with actigraphy

Can coenzyme Q10 and creatine slow the progress of Parkinson’s disease?

Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update

Neuropsychiatric and behavior changes in Parkinson’s disease patients with impulse control disorder after switching-off dopamine agonist by levodopa/carbidopa slow-release formulations

Microstructural changes in white and grey matter related to apathy, depression and anxiety in de novo Parkinson’s disease patients

Gait patterns in Parkinson’s disease with or without cognitive impairment

Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease

Socio-biological cues and saccade generation in Parkinson’s disease

Waking-day patterns of motor complications in Parkinson’s disease and the effect of ADS-5102

Effective diagnostic and treatment methods in vascular parkinsonism and Parkinson’s disease: Temporothythmal correction

New clinical research: The role of OncoMarkers in Parkinson’s disease and vascular parkinsonism

A randomized, double blind, placebo controlled, single ascending dose, safety and pharmacokinetic/pharmacodynamic study of INP103 in the presence of benserazide, to L-dopa responsive Parkinson’s patients

Spectral fingerprints of impulse control disorders in Parkinson’s disease

Treatment approaches to pain in Parkinson disease: A systematic review

REM sleep behavior disorder in parkinson disease: association with blunted heart rate variability on standing

Efficacy of incobotulinumtoxinA in patients with sialorrhoea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP)
Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhoea

Opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations: global impressions of change compared to placebo and entacapone

Poster
09:00 - 17:00

Exhibition Forum 3

Topic: Imaging, Genetics and Biomarkers

Cerebral microbleeds in dementia with Lewy bodies is not characteristic.

Assessment of clinic-biochemical features of Parkinson’s disease

Evaluation of the 70 kDa heat shock protein (Hsp70) plasma level in Parkinson’s disease and GBA-associated Parkinson’s disease patients

A rare fatal Familial parkinsonism in elderly with early respiratory failure

Application of convolutional neural networks in the diagnosis of Parkinson’s disease dementia based on magnetic resonance imaging

DAT scan abnormalities in juvenile Westphal variant of Huntington’s disease

Influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage

Association analysis of DRD2 rs2283265 and DRD1 rs4532 with Parkinson’s disease and Multiple system atrophy in a large Chinese population

Early brain metabolic changes in patients with Parkinson’s disease and its correlation to the risk of falling

Spg11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline

Speaker: Soham Desai (Anand, India)

Gene-lifestyle interactions in Parkinson’s disease

Coffee with the Professor
10:00 - 10:30

Coffee with the Professor 4

Chair: Tanya Simuni (Chicago, United States)

Parallel Tracks
10:30 - 12:00

Auditorium Lumière

Revisiting Tardive Dyskinesias

Chair: Emmanuel Broussolle (Lyon, France)

Setting the Record Straight: Nosology of Tardive Syndrome

Speaker: Daniel Truong (Fountain Valley, United States)


Speaker: Karen Frei (Loma Linda, United States)
Current Treatment Options for Tardive Dyskinesias
Speaker: Hubert Fernandez (Cleveland, United States)
11:30 - 12:00

Skills Workshops
10:30 - 12:00
Forum 1

Botulinum Toxin Use in Hyperkinetic Disorders
Chair: Dirk Dressler (Hannover, Germany)

Do's and Don'ts in Botulinum Toxin Injections for Cervical Dystonia
Speaker: Joohi Jimenez-Shahed (Houston, United States)
10:30 - 11:00

Injection Principles When Targeting the Face and Mouth
Speaker: Dirk Dressler (Hannover, Germany)
11:00 - 11:30

Pearls and Pitfalls in Botulinum Toxin Injections for Limb Dystonia and Spasticity
Speaker: Raymond Rosales (Quezon City, Philippines)
11:30 - 12:00

Examining the Hyperkinetic Patient
Chair: Irena Rektorova (Brno, Czech Republic)

How To Examine the Hyperkinetic Patient Like a Master Clinician
Speaker: Zoltan Mari (Cleveland, United States)
10:30 - 11:00

Recognizing Clues from the Eyes: Ophthalmological Examination in Movement Disorders
Speaker: Vivek Lal (Chandigarh, India)
11:00 - 11:30

Making a Confident Diagnosis of Functional Movement Disorders through Signs and Symptoms
Speaker: Alberto Espay (Cincinnati, United States)
11:30 - 12:00

Oral Poster Presentation
10:30 - 12:00
Forum 2
Foyer Forum

OP-04, Oral Poster Session IV - Imaging, Genetics and Biomarkers, Other Parkinsonian Disorders
Moderator: Jennifer Goldman (Chicago, United States)
Moderator: Eng-King Tan (Singapore, Singapore)

Imaging biomarkers for freezing of gait in patients with Parkinson´s disease
Pathway based genetic markers reveals relation between stroke and Parkinson’s disease
A novel co-activation pattern analysis of resting-state fMRI networks in Parkinson’s disease reveals reduced network dynamics that correlate with motor symptom severity
Early Parkinson’s disease is distinguished by a structural network backbone identified through graph theoretical analysis of diffusion MRI
Oligogenic inheritance in Parkinson disease explained by multiple mitochondrial and lysosomal gene mutations
Distinct between-network functional connectivity changes in Parkinson’s disease: A follow-up study
Diagnostic utility of a targeted resequencing technique of next generation sequencing in detecting copy number changes in PARK2

Investigating glucocerebrosidase (GBA) gene mutations in Parkinson's disease

Correlations between white matter lesions and cognitive impairment in Parkinson's disease

Diagnostic utility of acute levodopa challenge test: Beyond levodopa responsiveness

Onset and progression of pathologic atrophy in patients with Huntington disease in Uzbekistan

Frontal intermittent rhythmic delta activity (FIRDA) as a marker of Dementia with Lewy Body (DLB). A resting state conventional EEG study

Comparison of dystonia between Parkinson’s disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism

Striato-nigral and cortical 123I-FP-CIT dopaminergic deficits in dementia with Lewy bodies and Parkinson’s disease

---

Corporate Sessions
12:15 - 13:45

**Corporate Session 3: Answering the most relevant questions on Motor fluctuations in Parkinsons disease. Supported by an unrestricted grant of Neurocrine Biosciences & BIAL - Portela & C³, S.A.**

**Why do we keep developing drugs for motor fluctuations in Parkinsons disease?**
12:15 - 12:35
Speaker: Thomas Mueller (Berlin, Germany)

**Are the newest treatment options available for motor fluctuations worth their hype?**
12:35 - 12:55
Speaker: Stuart Isaacson (Boca Raton, FL, United States)

**Are the next generations of drugs under development for motor fluctuations more promising than our current armamentarium?**
12:55 - 13:15
Speaker: Stuart Isaacson (Boca Raton, FL, United States)

**Panel Discussion**
13:15 - 13:45

---

Plenary Session
13:45 - 15:15

**Hyperkinetic Disorders II - The Smaller Giants: Tremors, Ataxia and Movement Disorders in Children**

Chair: Maria Stamelou (Athens, Greece)
Chair: Stuart Isaacson (Boca Raton, FL, United States)

**Developing a Steady Approach to Shaking: The Classification of Tremors**
13:45 - 14:15
Speaker: Diego Torres-Russotto (Omaha, United States)

**Organizing the Chaotic World of Ataxia**
14:15 - 14:45
Speaker: Theresa Zesiewicz (Tampa, United States)

**The Unique Spectrum of Pediatric Movement Disorders**
14:45 - 15:15
Speaker: Jennifer Friedman (San Diego, United States)
Coffee with the Professor
15:15 - 15:45
Foyer Forum

Coffee with the Professor 5
Chair: Michael Schwarzschild (Boston, United States)

Parallel Tracks
15:45 - 17:15
Auditorium Lumière

Other Hyperkinetic Disorders
Chair: Rupam Borgohain (Hyderabad, India)

What's Old and New in Myoclonus?  
Speaker: John Caviness (Phoenix, United States)
15:45 - 16:15

The Evaluation and Treatment of Restless Legs and Periodic Leg Movements of Sleep  
Speaker: William Ondo (Houston, United States)
16:15 - 16:45

The Approach to Paroxysmal Movement Disorders  
Speaker: Eng-King Tan (Singapore, Singapore)
16:45 - 17:15

Skills Workshops
15:45 - 17:15
Forum 1

Surgical Therapies for Hyperkinetic Disorders
Chair: Marie Laure Welter (Paris, France)

DBS for Dystonia: Have We Finally Cracked the Code for Outcome Consistency?  
Speaker: Elena Moro (Grenoble, France)
15:45 - 16:15

DBS for the Treatment Tremors, Tourette’s and Chorea  
Speaker: Marie Laure Welter (Paris, France)
16:15 - 16:45

Ultrasound and Lesioning Therapies in Movement Disorders  
Speaker: Binit Shah (Charlottesvilles, United States)
16:45 - 17:15

Parallel Tracks
15:45 - 17:15
Forum 2

Rare and Misdiagnosed Movement Disorders
Chair: Rukmini Mridula Kandadai (Mumbai, India)

Spotting and Successfully Treating Wilson’s Disease  
Speaker: Peter Hedera (Nashville, United States)
15:45 - 16:15

One Only Sees What One Knows: Recognizing Autoimmune Disorders  
Speaker: Thien T. Lim (George Town, Malaysia)
16:15 - 16:45

The Diverse Spectrum of Metabolic and Infectious Movement Disorders  
Speaker: Yih-Ru Wu (Taoyuan, Taiwan)
16:45 - 17:15
OP-05, Oral Poster Session V - Parkinson Disease

Moderator: Alberto Albanese (Milan, Italy)

- Subcortical steps of visual processing are altered in de novo Parkinson’s disease patients
- Recommendations for the organization of team care in Parkinson’s disease: practice-based evidence from 20 expert centers around the world
- Effect of istradefylline on non-motor symptoms of Parkinson’s disease: a sub-analysis of a 1-year observational study in Japan (J-FIRST)
- Pain: a marker of prodromal Parkinsons disease?
- A randomized controlled trial of DA-9701 on gastric motility in patients with Parkinson’s disease
- Promoter identification and transcriptional regulation of the anti-inflammation gene CD200R1 in Parkinson’s disease
- Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions
- Long-term prognosis and survival of new Parkinson’s disease subtypes
- Acute dopaminergic neurotoxicity of alpha-synuclein oligomers is mediated by microglial cells
- Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease
- Early serotonergic lesion promotes the emergence and severity of motor symptoms in monkeys
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a phase 3 double-blind, placebo-controlled trial
- Therapeutic potential of a prolyl hydroxylase Inhibitor FG-4592 for Parkinson’s diseases
- Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson’s disease: A randomized clinical trial
- A novel adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease: a randomized controlled trial for efficacy and safety
- A novel mGlu4 compound displays anti-parkinsonian and anti-dyskinetic activity in primate models of Parkinson’s disease
- Efficacy and safety of incobotulinumtoxinA for upper-limb essential tremor in a randomised, double-blind, placebo-controlled trial using kinematics-guided clinical decision support
- Comparison of botulinum toxin injections in forearm FLexor plus EXtensor muscles versus flexor muscles alone for the treatment of Essential hand Tremor (FLEX ET)
- Beyond cerebellar involvement: Abnormal subcortical volumes in essential tremor

Spotlight Debate: Should we worry that pimavanserin might indeed increase mortality amongst Parkinson patients with psychosis? supported by Acadia® Pharmaceuticals with an unrestricted grant

Moderator: Karen Frei (Loma Linda, United States)

Yes, we should
Speaker: Daniel Weintraub (Philadelphia, United States)
No, we should not
Speaker: Zoltan Mari (Cleveland, United States)

Discussion/ Questions and Answers

Grand Parade of Movement Disorders
18:00 - 20:00
Auditorium Lumière

Grand Parade of Movement Disorders
Chair: Kailash Bhatia (London, United Kingdom)
Chair: Alberto Albanese (Milan, Italy)

Videos will be presented by
Speaker: Marie Vidailhet (Paris, France)
Speaker: Emmanuel Flamand-Roze (Paris, France)
Speaker: Maria Stamelou (Athens, Greece)
Speaker: Rukmini Mridula Kandadai (Mumbai, India)
Speaker: Thien T. Lim (George Town, Malaysia)
Speaker: Jirada Sringean (Bangkok, Thailand)
Speaker: Eugenia Tsoma (Uzhhorod, Ukraine)
Speaker: Wael Ibrahim (Cairo, Egypt)
Speaker: Soaham Desai (Anand, India)
Speaker: Chloe Laurencin (Lyon, France)
Plenary Session
08:00 - 10:00

Diagnostic and Therapeutic Updates - The Most Promising Diagnostic Tools and Therapies in Movement Disorders
Chair: Stephane Thobois (Lyon, France)
Chair: Elena Moro (Grenoble, France)

A Peek into the Next Generation of Diagnostic Tools in Movement Disorders
Speaker: Jon Stoessl (Vancouver, Canada)

Therapeutic Update I: Where Are We in PD Neuroprotection
Speaker: Tanya Simuni (Chicago, United States)

Therapeutic Update II: The Next Chapter in Symptomatic PD Treatment
Speaker: Hubert Fernandez (Cleveland, United States)

Therapeutic Update III: Where are Surgical Therapies Headed in Movement Disorders?
Speaker: Joachim Krauss (Hannover, Germany)

Coffee with the Professor
10:00 - 10:30

Coffee with the Professor 6
Chair: Marie Vidailhet (Paris, France)

Controversies in Movement Disorders - Debating Scientific and Practical Issues
Chair: Alessandro Di Rocco (New York, United States)
Chair: Erik Ch. Wolters (Amsterdam, Netherlands)

Pro: Yes, inflammation and immunity play an important role in PD pathogenesis
Speaker: Dennis Dickson (Jacksonville, FL, United States)

Con: No, inflammation and immunity do not play an important role in PD pathogenesis
Speaker: Etienne Hirsch (Paris, France)

Discussion

Pro: Yes, genetic testing is under-utilized in PD and other movement disorders
Speaker: Vincenzo Bonifati (Rotterdam, Netherlands)

Con: No, genetic testing is not under-utilized in PD and other movement disorders
Speaker: Andreas Puschmann (Lund, Sweden)

Discussion
Plenary Session
11:40 - 12:40
Auditorium Lumière

Parkinsonism and Related Disorders Journal: Special Session and Awards
Chair: Vincenzo Bonifati (Rotterdam, Netherlands)
Chair: Hubert Fernandez (Cleveland, United States)

Update on Parkinsonism and Related Disorders 11:40 - 11:50
Speaker: Hubert Fernandez (Cleveland, United States)
Speaker: Vincenzo Bonifati (Rotterdam, Netherlands)

Best Basic/Translational Science Articles published in PRD 11:50 - 12:10
Speaker: Andreas Puschmann (Lund, Sweden)

Best Clinical Science Articles published in PRD 12:10 - 12:30
Speaker: Eng-King Tan (Singapore, Singapore)

Best Poster Awards 12:30 - 12:40